What is the long-term trend for Spyre Therapeutics, Inc.'s other non-current liabilities?

Over 3 years (2020 to 2025), Spyre Therapeutics, Inc.'s other non-current liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $214K to $0.

What does other non-current liabilities mean?

Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Spyre Therapeutics, Inc. SYRE Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Bristol-Myers SquibbBMY

$4.85B+8.4%

Eli LillyLLY

$4.09B+78.5%

PfizerPFE

$14.2B+6.8%

Johnson & JohnsonJNJ

$10.21B-2.2%

Merck & Co.MRK

$7.64B+14.8%

AbbVieABBV

$34.11B+9.4%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s other non-current liabilities?: Spyre Therapeutics, Inc. (SYRE) reported other non-current liabilities of $1.29M in Q1 2026.
What is the long-term trend for Spyre Therapeutics, Inc.'s other non-current liabilities?: Over 3 years (2020 to 2025), Spyre Therapeutics, Inc.'s other non-current liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $214K to $0.
What does other non-current liabilities mean?: Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.